Is TTK Healthcare overvalued or undervalued?

As of 20 June 2025, TTK Healthcare's valuation grade has moved from fair to attractive, indicating a shift in its market perception. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 25.42, an EV to EBITDA of 29.72, and a Price to Book Value of 1.69, which suggest that the stock is trading at a reasonable valuation compared to its earnings and book value.
In comparison to its peers, TTK Healthcare's PE ratio is lower than Sun Pharma's 34.92 and Divi's Lab's 79.84, both of which are categorized as expensive. Additionally, TTK's EV to EBITDA ratio is more favorable than that of Sun Pharma, which stands at 24.66. Despite recent underperformance with a year-to-date return of -10.20% compared to the Sensex's 5.46%, TTK Healthcare's strong position relative to its peers supports the conclusion that it is undervalued in the current market.